CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 3.14 million shares for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2018-03-08
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-12-31 was 2.74M shares.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-09-30 was 0.00 shares.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2012-12-31 was 2.09M shares.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2012-09-30 was 0.00 shares.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 3.14M shares, a 18.47% increase from fiscal 2013.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 2.65M shares, a 18.89% decline from fiscal 2012.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 3.27M shares, a 99.09% increase from fiscal 2011.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2011 was 1.64M shares, a 17.04% decline from fiscal 2010.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|---|---|
| 2014-12-31 | 2.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | 2.74M shares derived: sum of 2 quarters · filed 2015-02-24 | 3.14M shares 10-K · filed 2015-02-24 | |||
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | 400.00K shares 10-Q · filed 2014-11-10 | ||||
| 2014-06-30 | 400.00K shares 10-K · filed 2018-03-08 | 400.00K shares 10-Q · filed 2014-08-07 | ||||
| 2014-06-02 | 400.00K shares 10-K · filed 2018-03-08 | |||||
| 2014-02-28 | 640.00K shares 10-K · filed 2018-03-08 | |||||
| 2014-02-18 | 640.00K shares 10-K · filed 2018-03-08 | |||||
| 2013-12-31 | 2.65M shares 10-K · filed 2015-02-24 | |||||
| 2012-12-31 | 2.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | 2.09M shares derived: sum of 2 quarters · filed 2015-02-24 | 3.27M shares 10-K · filed 2015-02-24 | |||
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | 1.18M shares 10-Q · filed 2012-11-06 | ||||
| 2012-06-30 | 1.18M shares 10-Q · filed 2012-08-09 | |||||
| 2011-12-31 | 1.64M shares 10-K · filed 2014-03-13 | |||||
| 2010-12-31 | 1.98M shares 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |